OnKure Therapeutics, Inc. OKUR Business Segments — Net Income Loss
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by OnKure Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The official record: OnKure Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about OnKure Therapeutics, Inc.'s business segments — net income loss.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is OnKure Therapeutics, Inc.'s business segments — net income loss?
- OnKure Therapeutics, Inc. (OKUR) reported business segments — net income loss of -$15.62M in Q1 2026.
- How has OnKure Therapeutics, Inc.'s business segments — net income loss changed year-over-year?
- OnKure Therapeutics, Inc.'s business segments — net income loss increased by 8.1% year-over-year, from -$17M to -$15.62M.
- What does business segments — net income loss mean?
- Measures the total profitability or loss generated by the clinical research segment after accounting for all direct and allocated operating expenses. For clinical-stage biopharmaceutical companies, this metric typically reflects the net burn rate of the research division. It serves as a primary indicator of the segment's financial sustainability and the scale of investment required for drug development.